Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue Mounier 72 bte B1.72.02, 1200, Brussels, Belgium.
Medical School, Université catholique de Louvain, Brussels, Belgium.
Drugs Aging. 2019 May;36(5):453-459. doi: 10.1007/s40266-018-00635-8.
Older persons are at significant risk of drug-related admissions (DRAs). We previously demonstrated that 27% of hospitalizations in geriatric patients were associated with potentially inappropriate medicines (PIMs) and/or potential prescribing omissions (PPOs) identified by the Screening Tool of Older People's Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 1 (v). The updated STOPP/START criteria version 2 (v) comprised a 31% increase in prescribing criteria.
As a secondary analysis of our study conducted in 2008, we aimed to compare the prevalence and types of DRAs identified by STOPP/START.v and STOPP/START.v.
We applied the STOPP/START.v criteria to a subset of 100 consecutively admitted geriatric patients selected from our original cross-sectional study of 302 patients. A geriatrician and a pharmacist adjudicated whether the identified PIMs and PPOs were related to acute hospitalization. Admissions were defined as DRAs if the identified PIM(s) and/or PPO(s) were related to the main cause of admission or played a significant contributory role in the admission.
The median patient age was 83 years and the median number of medications at home was 8. Compared with STOPP/START.v, STOPP/START.v not only yielded more instances of inappropriate prescribing but also targeted significantly more PIMs and PPOs associated with preventable DRAs (23% vs. 40% of all admissions, p < 0.001). PIMs of fall-risk-increasing drugs, and PPOs of musculoskeletal and cardiovascular system drugs, were most frequently associated with DRAs.
The latter instances of inappropriate prescribing with major clinical relevance warrant particular attention during medication review in older persons.
老年人面临着与药物相关的入院(DRAs)的重大风险。我们之前的研究表明,老年患者中有 27%的住院与潜在不适当药物(PIMs)和/或潜在的处方遗漏(PPOs)有关,这些药物和遗漏是通过老年人处方筛选工具/筛选工具以警示正确治疗(STOPP/START)标准版本 1(v)确定的。更新的 STOPP/START 标准版本 2(v)增加了 31%的处方标准。
作为我们在 2008 年进行的研究的二次分析,我们旨在比较 STOPP/START.v 和 STOPP/START.v 确定的 DRAs 的流行率和类型。
我们将 STOPP/START.v 标准应用于从我们最初的 302 名患者的横断面研究中选择的 100 名连续入院的老年患者的亚组。老年病医生和药剂师裁定确定的 PIMs 和 PPOs 是否与急性住院有关。如果确定的 PIM(s)和/或 PPO(s)与主要入院原因有关,或者在入院中起重要作用,则将入院定义为 DRAs。
患者的中位年龄为 83 岁,中位居家用药数为 8 种。与 STOPP/START.v 相比,STOPP/START.v 不仅产生了更多不适当的处方实例,而且还针对与可预防 DRAs 相关的更多 PIMs 和 PPOs(所有入院的 23%与 40%,p<0.001)。增加跌倒风险的药物的 PIMs 和肌肉骨骼和心血管系统药物的 PPOs 与 DRAs 最相关。
这些具有重大临床相关性的不适当处方实例尤其需要在老年人药物审查中引起关注。